Thierry VandenDriessche

List of Publications by Year
in descending order

35	1,268	471477 17	395678 33
papers	citations	h-index	g-index

38	38	38	1922
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovascular Research, 2015, 108, 4-20.	3.8	129
2	Liver-directed lentiviral gene therapy in a dog model of hemophilia B. Science Translational Medicine, 2015, 7, 277ra28.	12.4	118
3	Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nature Communications, 2020, 11, 5432.	12.8	105
4	Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells. Nature Protocols, 2015, 10, 941-958.	12.0	98
5	Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood, 2012, 120, 4517-4520.	1.4	84
6	Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells. Nucleic Acids Research, 2018, 46, 8275-8298.	14.5	78
7	Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy. Blood, 2014, 123, 3195-3199.	1.4	73
8	Liver-Specific Transcriptional Modules Identified by Genome-Wide In Silico Analysis Enable Efficient Gene Therapy in Mice and Non-Human Primates. Molecular Therapy, 2014, 22, 1605-1613.	8.2	71
9	Preclinical and clinical advances in transposon-based gene therapy. Bioscience Reports, 2017, 37, .	2.4	68
10	Transposons: Moving Forward from Preclinical Studies to Clinical Trials. Human Gene Therapy, 2017, 28, 1087-1104.	2.7	56
11	A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice. Molecular Therapy, 2017, 25, 1815-1830.	8.2	52
12	Efficient InÂVivo Liver-Directed Gene Editing Using CRISPR/Cas9. Molecular Therapy, 2018, 26, 1241-1254.	8.2	52
13	Hyperactive PiggyBac Transposons for Sustained and Robust Liver-targeted Gene Therapy. Molecular Therapy, 2014, 22, 1614-1624.	8.2	48
14	Genome-wide Computational Analysis Reveals Cardiomyocyte-specific Transcriptional Cis-regulatory Motifs That Enable Efficient Cardiac Gene Therapy. Molecular Therapy, 2015, 23, 43-52.	8.2	36
15	AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model. Human Molecular Genetics, 2017, 26, 1353-1364.	2.9	26
16	piggyBactransposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts. Nucleic Acids Research, 2016, 44, 744-760.	14.5	25
17	Hemophilia Gene Therapy: Ready for Prime Time?. Human Gene Therapy, 2017, 28, 1013-1023.	2.7	25
18	Universal allogeneic CAR TÂcells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy. Molecular Therapy, 2022, 30, 3155-3175.	8.2	21

#	Article	IF	Citations
19	Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia, 2020, 26, 443-449.	2.1	15
20	A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity. Human Gene Therapy, 2018, 29, 927-937.	2.7	10
21	Hyperactive Factor IX Padua: A Game-Changer for Hemophilia Gene Therapy. Molecular Therapy, 2018, 26, 14-16.	8.2	10
22	Validation of miR-20a as a Tumor Suppressor Gene in Liver Carcinoma Using Hepatocyte-Specific Hyperactive piggyBac Transposons. Molecular Therapy - Nucleic Acids, 2020, 19, 1309-1329.	5.1	9
23	Comprehensive transcriptome-wide analysis of spliceopathy correction of myotonic dystrophy using CRISPR-Cas9 in iPSCs-derived cardiomyocytes. Molecular Therapy, 2022, 30, 75-91.	8.2	9
24	Distinct transduction of muscle tissue in mice after systemic delivery of AAVpo1 vectors. Gene Therapy, 2020, 27, 170-179.	4.5	8
25	Gene Therapy For Hemophilia B Using CB 2679d-GT: A Novel Factor IX Variant With Higher Potency Than Factor IX Padua. Blood, 2021, 137, 2902-2906.	1.4	8
26	CRISPR/Cas9 Flexes Its Muscles: In Vivo Somatic Gene Editing for Muscular Dystrophy. Molecular Therapy, 2016, 24, 414-416.	8.2	7
27	Moving Forward Toward a Cure for Hemophilia B. Molecular Therapy, 2015, 23, 809-811.	8.2	5
28	Dose-Dependent Microdystrophin Expression Enhancement in Cardiac Muscle by a Cardiac-Specific Regulatory Element. Human Gene Therapy, 2021, 32, 1138-1146.	2.7	5
29	Hitting the Target Without Pulling the Trigger. Molecular Therapy, 2015, 23, 4-6.	8.2	3
30	Immunology of Gene and Cell Therapy. Molecular Therapy, 2020, 28, 691-692.	8.2	3
31	Genetic and Epigenetic Modification of Rat Liver Progenitor Cells via HNF4Î± Transduction and 5â€™ Azacytidine Treatment: An Integrated miRNA and mRNA Expression Profile Analysis. Genes, 2020, 11, 486.	2.4	2
32	AAV Capsid Engineering: Zooming in on the Target. Human Gene Therapy, 2017, 28, 373-374.	2.7	1
33	1: INTRODUCTION. ICP Textbooks in Biomolecular Sciences, 2014, , 3-6.	0.1	0
34	Getting Into the Rhythm With CRISPR. Circulation Research, 2018, 123, 928-930.	4.5	0
35	The RNA World: The Best of Times, the Worst of Times. Human Gene Therapy, 2021, 32, 975-977.	2.7	0